Best Health Care Grants in American Samoa

The NIH Midcareer Investigator Award in Patient-Oriented Research (K24) aims to support mid-career health professionals in conducting patient-oriented research while mentoring clinical residents and junior faculty. This grant offers protected time for research, ensuring participants can focus on impactful studies and foster the next generation of clinical researchers. Key deadlines for applications range from June 2024 to February 2027, with specific dates for standard, renewal, and AIDS-related submissions.

The NIH Midcareer Investigator Award in Patient-Oriented Research (K24) supports mid-career health-professional doctorates by providing protected time for patient-oriented research (POR). This grant also enables recipients to serve as research mentors for clinical residents, fellows, and junior faculty. Key deadlines for applications span from June 2024 to February 2027, ensuring ample opportunities for interested applicants to engage in impactful research and mentoring.

The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for research on isolated human islets as a diabetes treatment. This initiative aims to gather data from clinical trials, aiding the research community in future publications and trial designs. While applications are not currently being accepted, potential applicants are encouraged to start forming collaborations and consider applying when the opportunity opens.

The NextTech initiative aims to propel the development of cutting-edge diagnostic and therapeutic devices that address critical health challenges. This funding opportunity encourages researchers to innovate solutions that can move from concept to clinical readiness, specifically targeting technologies aligned with the NIH's BRAIN and HEAL initiatives. Successful proposals will focus on overcoming barriers to human trials, ensuring that new medical devices can effectively monitor and treat neurological and addiction-related disorders.

The NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01) invites applications to support clinical trials that require FDA oversight, aim to establish efficacy, or pose significant risks. This initiative, managed by the NIH, seeks to enhance interventions for communication disorders and encourages collaboration between NIDCD Project Scientists and investigators. Proposals are due by 5 PM local time, with Letters of Intent recommended 30 days prior to the deadline.

The DoW Vision Research Program's FY26 Translational Research Award aims to accelerate the development of innovative drugs, devices, or clinical guidelines ready for clinical trials. It supports preclinical studies and pilot trials, ensuring alignment with specified VRP Focus Areas. Key features include a requirement for regulatory expertise in drug/device development and a unique Partnering Principal Investigator option. Review criteria focus on research rationale, strategy, feasibility, and impact, enhancing military health outcomes.

The FY26 Vision Research Program Clinical Trial Award supports the swift execution of clinical trials aimed at improving treatments for service-connected eye injuries and visual dysfunction. This award emphasizes the need for regulatory compliance, including IND/IDE submissions, and requires documentation confirming the application's active status by March 1, 2027. Review criteria focus on clinical impact, research feasibility, recruitment strategies, and ethical considerations, ensuring relevance to military health.

The NIH Independent Scientist Award (K02) supports promising scientists in their research endeavors, providing salary and protected time for three to five years. This award is designed for newly independent scientists who can demonstrate the necessity for focused research to advance their careers. The program specifically targets basic experimental studies involving human participants, aligning with NIH's clinical trial definitions and aims to foster significant contributions to various scientific fields.

The FY26 Vision Research Program's Investigator-Initiated Research Award (IIRA) offers funding for innovative research addressing eye injury and visual dysfunction due to military exposure. This award supports preclinical to early translational studies aligned with specific focus areas. Unique features include two funding levels and a Partnering Principal Investigator Option. Applications undergo rigorous peer review based on research rationale, strategy, and impact, with potential for sharing with the National Eye Institute for additional funding consideration.

The DoW Vision, Mentored Clinical Research Award supports innovative, patient-focused research on vision injuries by military or civilian clinicians in training. This award facilitates high-impact studies or the collection of data for future research, ensuring alignment with FY26 VRP Focus Areas. Key participants include a Principal Investigator and a clinician in training, with a focus on feasibility and impact. Approval from the Institutional Review Board is required for funding consideration.

The FY26 Pancreatic Cancer Research Program (PCARP) Idea Development Award promotes innovative, high-risk research aimed at significant advancements for pancreatic cancer outcomes. This award supports projects with preliminary data, focusing on impactful discoveries. It features a Partnering Principal Investigator option, enhancing funding for collaborations between experienced mentors and early-career researchers. All applications must align with the FY26 PCARP Focus Areas, ensuring relevance and potential for transformative results in pancreatic cancer research.

The NIH R25 program aims to enhance inclusivity in research education by supporting activities that encourage individuals from diverse backgrounds to pursue careers in substance use and addiction sciences. This initiative focuses on skills development courses and research experiences, particularly targeting underrepresented groups in biomedical and behavioral sciences. Applications are due by 5:00 PM local time of the applicant organization, with optional Letters of Intent encouraged 30 days prior to the full proposal deadline.

The NINDS Exploratory Clinical Trials for Small Business (R41/R42) program supports Small Business Concerns in conducting investigator-initiated exploratory clinical trials. This funding opportunity emphasizes projects that align with the NINDS mission, evaluating diverse products including drugs, biologics, and devices. Only STTR Phase II and Fast-Track applications are eligible, fostering innovation in neurological disorder treatments. Applications are due by 5:00 PM local time, with optional Letters of Intent encouraged 30 days prior to the deadline.

The NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required) grant supports small businesses in conducting innovative clinical trials relevant to neurological disorders. This funding opportunity encourages investigator-initiated projects evaluating drugs, devices, and therapies aligned with NINDS goals. Applications are accepted only from SBIR Phase II and Fast-Track applicants, with a submission deadline of 5:00 PM local time. Letters of Intent are encouraged 30 days prior to the full proposal deadline.

The Miniaturization and Automation of Tissue Chip Systems (MATChS) initiative by the NIH aims to advance biomedical research through the development of automated tissue chip platforms. This program encourages small businesses to propose innovative technologies that enhance data acquisition and analysis while minimizing manual handling. Funded projects will create efficient, miniaturized systems vital for drug development and other research applications. Collaboration with NIH staff is expected to ensure milestones and commercial pathways are effectively established.

The Limited Competition Small Grant Program supports NCATS CTSA Program KL2 scholars, enhancing their transition to independent academic translational scientists. This R03 funding facilitates various research projects, including pilot studies and methodology development, aimed at generating preliminary data for future R01 applications. The program is designed for short-term projects utilizing limited resources, promoting innovative research in clinical and translational science.

The Miniaturization and Automation of Tissue Chip Systems (MATChS) initiative supports the development of advanced technologies for automated tissue chip platforms. This funding opportunity, provided by the NIH, aims to enhance drug development and biomedical research by enabling high-throughput automated measures and online data analysis. Successful applications will demonstrate collaboration with NIH staff to achieve project milestones and pathways to commercialize these innovative systems, ultimately increasing the accessibility of miniaturized solutions in research.

The Mentored Quantitative Research Development Award (K25) aims to attract researchers in quantitative science and engineering to focus on NIH-relevant health research. This award provides protected time for supervised study and research, allowing professionals from fields like mathematics, statistics, and engineering to integrate their expertise into health-related studies. The K25 is specifically for lead investigators of independent clinical trials or related studies, fostering innovation in clinical research and career development.

The Mentored Quantitative Research Development Award (K25) aims to engage skilled professionals in NIH-relevant research, enhancing their expertise in addressing health-related issues. This award supports individuals with backgrounds in quantitative sciences and engineering, providing them with dedicated time for supervised research and study. Key application deadlines span from June 2024 to February 2027, emphasizing the program's commitment to fostering innovative research in health and disease.

The Aging Research Dissertation Awards aim to enhance diversity in the scientific workforce by funding research on aging and related health conditions. The program encourages applicants from underrepresented backgrounds to apply for dissertation awards that align with the National Institutes of Health's strategic priorities. Key deadlines for applications include February 16, June 16, and October 16 for the years 2024 through 2026.

The Mentored Quantitative Research Development Award (K25) aims to attract researchers with quantitative science backgrounds to NIH-relevant studies. It provides support and protected time for professionals to integrate their expertise in areas like mathematics and statistics with health research. Notably, it does not support independent clinical trials, focusing instead on collaborative experiences under mentorship. The application process involves specific deadlines for submissions, including standard, renewal, and AIDS-related grants, encouraging diverse participation in significant health research.

The NCI Pathway to Independence Award (K99/R00) supports early-stage postdoctoral researchers transitioning to independent faculty positions. This funding opportunity encourages talented individuals with clinical or research doctoral degrees to lead independent clinical trials. Applicants should aim to foster research careers in cancer control, prevention, and data sciences. This initiative provides essential support during the transition from mentored positions to independent research roles, enhancing the pool of independent investigators in cancer research.

The NCI Pathway to Independence Award (K99/R00) aims to support early-stage postdoctoral researchers transitioning to independent faculty positions. This initiative focuses on talented individuals with doctoral degrees in research or clinical fields, providing essential NCI funding during this key career juncture. Researchers engaged in cancer control, prevention, and data sciences are encouraged to apply for this opportunity, which emphasizes experimental studies with human participants, thus aligning with NIH's clinical trial definitions.

The NCI Pathway to Independence Award (K99/R00) supports early-stage postdoctoral researchers aiming to transition to independent faculty positions. It encourages candidates with doctoral degrees in research or clinical fields to apply, particularly those in cancer control and prevention. This funding opportunity facilitates a quick shift from mentored research to independent careers, providing essential support for awardees to establish competitive research programs without leading their own clinical trials.

The NIH Mentored Research Scientist Development Award (K01) aims to support emerging scientists by providing protected time for career development in biomedical, behavioral, or clinical sciences. This award, effective for three to five years, encourages research independence and may be beneficial for those transitioning fields or returning from a hiatus due to personal circumstances. Deadlines for applications vary, with important dates set for standard, renewal, and AIDS-related submissions.

The Limited Competition grant supports High Impact Specialized Innovation Programs to enhance clinical and translational science capabilities at UM1 CTSA Program Hubs. Eligible applicants include primary UM1 CTSA hub organizations, aiming to address significant gaps in research and development. Successful proposals will foster foundational innovations for broader dissemination among CTSA hubs, paving the way for future advancements in clinical practices and research methodologies.

The NIH Mentored Research Scientist Development Award (K01) supports early-career scientists with up to five years of protected time for intensive research training in biomedical, behavioral, or clinical sciences. This award is tailored for those pursuing independence in research and is particularly beneficial for individuals transitioning fields or returning from a hiatus. Importantly, applicants must not lead independent clinical trials but may participate in trials overseen by mentors.